Ribatti D: The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des. 2009, 15 (4): 345-352. 10.2174/138161209787315855.
Article
CAS
PubMed
Google Scholar
Gasparini G: Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2001, 2 (12): 733-740. 10.1016/S1470-2045(01)00587-3.
Article
CAS
PubMed
Google Scholar
Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999, 94 (12): 4143-4155.
CAS
PubMed
Google Scholar
Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004, 4 (6): 423-436. 10.1038/nrc1369.
Article
CAS
PubMed
Google Scholar
Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP: CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997, 138 (3): 707-717. 10.1083/jcb.138.3.707.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP: Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis. 1999, 3 (2): 147-158. 10.1023/A:1009018702832.
Article
CAS
PubMed
Google Scholar
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006, 7 (5): 359-371. 10.1038/nrm1911.
Article
CAS
PubMed
Google Scholar
Carmeliet P: Manipulating angiogenesis in medicine. J Intern Med. 2004, 255 (5): 538-561. 10.1111/j.1365-2796.2003.01297.x.
Article
PubMed
Google Scholar
Jain RK: Barriers to drug delivery in solid tumors. Sci Am. 1994, 271 (1): 58-65. 10.1038/scientificamerican0794-58.
Article
CAS
PubMed
Google Scholar
Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307 (5706): 58-62. 10.1126/science.1104819.
Article
CAS
PubMed
Google Scholar
Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64 (11): 3731-3736. 10.1158/0008-5472.CAN-04-0074.
Article
CAS
PubMed
Google Scholar
Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003, 88 (12): 1979-1986. 10.1038/sj.bjc.6601005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10 (2): 145-147. 10.1038/nm988.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005, 23 (5): 939-952. 10.1200/JCO.2005.07.093.
Article
CAS
PubMed
Google Scholar
Fathers KE, Stone CM, Minhas K, Marriott JJ, Greenwood JD, Dumont DJ, Coomber BL: Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am J Pathol. 2005, 167 (6): 1753-1762.
Article
CAS
PubMed
PubMed Central
Google Scholar
Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS: Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther. 2007, 6 (8): 2280-2289. 10.1158/1535-7163.MCT-07-0181.
Article
CAS
PubMed
Google Scholar
Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285 (21): 1182-1186. 10.1056/NEJM197111182852108.
Article
CAS
PubMed
Google Scholar
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-2342. 10.1056/NEJMoa032691.
Article
CAS
PubMed
Google Scholar
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003, 21 (1): 60-65. 10.1200/JCO.2003.10.066.
Article
CAS
PubMed
Google Scholar
Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007, 25 (30): 4793-4799. 10.1200/JCO.2007.12.8637.
Article
CAS
PubMed
Google Scholar
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008, 26 (11): 1810-1816. 10.1200/JCO.2007.14.5375.
Article
CAS
PubMed
Google Scholar
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008, 26 (20): 3403-3410. 10.1200/JCO.2007.15.9020.
Article
CAS
PubMed
Google Scholar
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008, 26 (4): 650-656. 10.1200/JCO.2007.13.9303.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15 (3): 232-239. 10.1016/j.ccr.2009.01.021.
Article
CAS
PubMed
PubMed Central
Google Scholar
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15 (3): 220-231. 10.1016/j.ccr.2009.01.027.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu JL, Coomber BL, Kerbel RS: A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation. 2002, 70 (9-10): 599-609. 10.1046/j.1432-0436.2002.700913.x.
Article
PubMed
Google Scholar
Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008, 8 (8): 592-603. 10.1038/nrc2442.
Article
CAS
PubMed
PubMed Central
Google Scholar
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60 (7): 1878-1886.
CAS
PubMed
Google Scholar
Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS: Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 2006, 66 (3): 1664-1674. 10.1158/0008-5472.CAN-05-2598.
Article
CAS
PubMed
Google Scholar
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002, 62 (10): 2731-2735.
CAS
PubMed
Google Scholar
Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R: Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004, 64 (5): 1570-1574. 10.1158/0008-5472.CAN-03-3126.
Article
CAS
PubMed
Google Scholar
Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA. 2003, 100 (22): 12917-12922. 10.1073/pnas.2135406100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G: Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008, 98 (10): 1619-1629. 10.1038/sj.bjc.6604352.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000, 105 (8): R15-24. 10.1172/JCI8829.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shahrzad S, Shirasawa S, Sasazuki T, Rak JW, Coomber BL: Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene. 2008, 27 (26): 3729-3738. 10.1038/sj.onc.1211031.
Article
CAS
PubMed
Google Scholar
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E: Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008, 25 (4): 431-6. 10.1007/s12032-008-9058-y.
Article
PubMed
Google Scholar
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002, 99 (17): 11393-11398. 10.1073/pnas.172398299.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lohela M, Bry M, Tammela T, Alitalo K: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009, 21 (2): 154-165. 10.1016/j.ceb.2008.12.012.
Article
CAS
PubMed
Google Scholar
Suchting S, Eichmann A: Jagged gives endothelial tip cells an edge. Cell. 2009, 137 (6): 988-990. 10.1016/j.cell.2009.05.024.
Article
CAS
PubMed
Google Scholar
Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH: The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 2009, 137 (6): 1124-1135. 10.1016/j.cell.2009.03.025.
Article
CAS
PubMed
Google Scholar
Jakobsson L, Bentley K, Gerhardt H: VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans. 2009, 37 (Pt 6): 1233-1236. 10.1042/BST0371233.
Article
CAS
PubMed
Google Scholar
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004, 6 (6): 553-563.
CAS
PubMed
Google Scholar
Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007, 13 (13): 3942-3950. 10.1158/1078-0432.CCR-07-0278.
Article
CAS
PubMed
Google Scholar
Ellis LM: Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006, 33 (5 Suppl 10): S1-7. 10.1053/j.seminoncol.2006.08.002.
Article
CAS
PubMed
Google Scholar
Miller DW, Vosseler S, Mirancea N, Hicklin DJ, Bohlen P, Volcker HE, Holz FG, Fusenig NE: Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol. 2005, 167 (5): 1389-1403.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 2005, 65 (4): 1294-1305. 10.1158/0008-5472.CAN-03-3986.
Article
CAS
PubMed
Google Scholar
Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002, 160 (3): 985-1000.
Article
PubMed
PubMed Central
Google Scholar
Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2003, 163 (5): 1801-1815.
Article
PubMed
PubMed Central
Google Scholar
Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, Ito M, Chayama K: Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer. 2003, 105 (2): 176-181. 10.1002/ijc.11068.
Article
CAS
PubMed
Google Scholar
Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL: Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001, 158 (4): 1325-1334.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bindra RS, Glazer PM: Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005, 569 (1-2): 75-85.
Article
CAS
PubMed
Google Scholar
Huang LE, Bindra RS, Glazer PM, Harris AL: Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med. 2007, 85 (2): 139-148. 10.1007/s00109-006-0133-6.
Article
CAS
PubMed
Google Scholar
Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, Coomber BL: Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res. 2005, 65 (18): 8134-8141. 10.1158/0008-5472.CAN-05-0713.
Article
CAS
PubMed
Google Scholar
Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005, 8 (4): 299-309. 10.1016/j.ccr.2005.09.005.
Article
CAS
PubMed
Google Scholar